The duracopeptide injection (BA5101) independently developed by Boan Biotech has completed phase III clinical trials in China and plans to submit a marketing application; CGN New Energy's subsidiary plans to appoint China Energy Construction Jiangsu Design Institute to carry out construction projects with a contract price of about 1,186 billion yuan
Important matters:
Boan Biotech (06955) self-developed duracopeptide injection (BA5101) has completed phase III clinical trials in China and plans to submit a marketing application
CGN New Energy (01811) subsidiary plans to appoint China Energy Construction Jiangsu Design Institute to carry out construction projects with a contract price of about 1,186 billion yuan
Hong Kong Dongyangguang Changjiang Pharmaceutical (01558) shareholder Hong Kong Dongyangyang transferred about 25.71% of the company's shares to Guangdong Dongyangyang Pharmaceutical with a total consideration of about HK$2,067 billion and resumed trading on March 11
Bohai Bank (09668) plans to sell credit assets for 3,967 billion yuan
Xiansheng Pharmaceutical (02096): SIM0500 (humanized GPRC5D-BCMA-CD3 trispecific antibody) new drug clinical trial application approved by the US Food and Drug Administration
Operating performance:
Shunyu Optical Technology (02382) shipped about 104 million mobile lenses in February, up 1.1% month-on-month and 29.4% year-on-year
Dongfeng Group Co., Ltd. (00489): The cumulative car sales volume in January-February was 331,000 vehicles, up about 26.2% year on year
Longyuan Electric Power (00916) completed a cumulative total of 13.4672 million megawatt-hours in the first 2 months, an increase of 5.55% year-on-year
China Tobacco Hong Kong (06055) announced annual results. Profit attributable to shareholders was HK$599 million, up 60% year-on-year final dividend of HK$0.32 per share
ZTE (00763) announced annual results, net profit of 9.326 billion yuan, a year-on-year increase of 15.41%, and proposed a final dividend of 6.83 yuan per 10 shares
Haohai Biotechnology (06826) announced its 2023 annual results, with net profit of 416 million yuan to mother, a sharp increase of 130.58% over the previous year
For more details, please refer to Zhitong Financial Network ()